Psoriasis Biosimilars Market Global Report 2026 Market Report Infographic Image

Published : April 2026

Pages : 250

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Psoriasis Biosimilars Market Report 2026

Name: Psoriasis Biosimilars Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Global Outlook – By Drug Class (TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, Other Biosimilars), By Disease Type (Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis), By Route Of Administration (Subcutaneous, Intravenous, Oral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, Strategies, and Forecast to 2035

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Purchase This Report Download Sample PDF

Item added to cart!

Psoriasis Biosimilars Market Overview

• Psoriasis Biosimilars market size has reached to $8.16 billion in 2025

• Expected to grow to $13.79 billion in 2030 at a compound annual growth rate (CAGR) of 11%

• Growth Driver: Rising Psoriatic Arthritis Diagnoses Fueling The Growth Of The Market Due To Increasing Early Detection And Cost-Effective Treatment Demand

• Market Trend: Launch Of First Ustekinumab Biosimilar Autoinjector Enhances Plaque Psoriasis Treatment Options

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Psoriasis Biosimilars Market?

Psoriasis biosimilars are biologic medications designed to closely mimic the structure, function, safety, and effectiveness of already approved reference biologics used in the treatment of moderate to severe psoriasis. These biosimilars provide a cost-effective alternative to original biologics, helping to improve patient access to advanced therapies without compromising clinical performance or quality.

The main types of drug classes in psoriasis biosimilars are TNF-alpha inhibitors, infliximab, etanercept, adalimumab, and other biosimilars. TNF-alpha inhibitors are a class of biologic drugs that block tumor necrosis factor-alpha (TNF-a), a protein responsible for inflammation in psoriasis. It is used for various disease types, such as plaque psoriasis, guttate psoriasis, inverse psoriasis, and pustular psoriasis, and administered through subcutaneous, intravenous, oral, and topical routes. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Psoriasis Biosimilars Market Global Report 2026 Market Report bar graph

What Is The Psoriasis Biosimilars Market Size and Share 2026?

The psoriasis biosimilars market size has grown rapidly in recent years. It will grow from $8.16 billion in 2025 to $9.08 billion in 2026 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to high cost of reference biologics, limited patient access to treatment, growing prevalence of moderate to severe psoriasis, increasing physician awareness and prescriptions, initial approvals of TNF-alpha inhibitors.

What Is The Psoriasis Biosimilars Market Growth Forecast?

The psoriasis biosimilars market size is expected to see rapid growth in the next few years. It will grow to $13.79 billion in 2030 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to launch of new biosimilars for infliximab, etanercept, and adalimumab, expansion of hospital and online pharmacy networks, increasing healthcare expenditure on dermatology, rising adoption of patient assistance programs, growth in clinical trials for novel biosimilars. Major trends in the forecast period include rising adoption of cost-effective psoriasis biosimilars, increased focus on patient access and affordability, growth in subcutaneous and intravenous administration routes, expansion of hospital and retail pharmacy distribution channels, development of targeted therapies for different psoriasis types.

Book your 30 minutes free consultation with our research experts

Global Psoriasis Biosimilars Market Segmentation

1) By Drug Class: TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, Other Biosimilars

2) By Disease Type: Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis

3) By Route Of Administration: Subcutaneous, Intravenous, Oral, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By TNF-Alpha Inhibitors: Monoclonal Antibody Biosimilars, Fusion Protein Biosimilars

2) By Infliximab: Remicade Biosimilars, CT-P13 Biosimilars

3) By Etanercept: Enbrel Biosimilars, SB4 Biosimilars

4) By Adalimumab: Humira Biosimilars, ABP 501 Biosimilars

5) By Other Biosimilars: Ustekinumab Biosimilars, Secukinumab Biosimilars

What Is The Driver Of The Psoriasis Biosimilars Market?

The rising psoriatic arthritis diagnosis rates are expected to propel the growth of the psoriasis biosimilars market going forward. Psoriatic arthritis refers to a chronic autoimmune condition that causes inflammation in the joints and skin, often affecting individuals with a history of psoriasis. The psoriatic arthritis diagnosis rates are increasing, particularly due to improved screening protocols among individuals with psoriasis, which enable earlier detection and more accurate diagnosis by identifying subtle joint symptoms that might have previously gone unnoticed. Psoriasis biosimilars help manage psoriatic arthritis by providing affordable alternatives to biologic therapies, effectively reducing joint inflammation and skin symptoms. For instance, in August 2025, according to the National Psoriasis Foundation (NPF), a US-based non-profit patient advocacy organization, psoriatic arthritis affects roughly 1 in 3 people living with psoriasis, and as many as 2.4 million Americans live with psoriatic arthritis, while more than 15% of people with psoriasis may also have undiagnosed psoriatic arthritis, highlighting both increasing recognition and persistent underdiagnosis of the condition. Therefore, the rising psoriatic arthritis diagnosis rates are driving the growth of the psoriasis biosimilars industry.

Key Players In The Global Psoriasis Biosimilars Market

Major companies operating in the psoriasis biosimilars market are Pfizer Inc., Amgen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis Co. Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Alvotech hf.

Global Psoriasis Biosimilars Market Trends and Insights

Major companies operating in the psoriasis biosimilars market are focusing on introducing innovative solutions, such as biosimilars for plaque psoriasis, to enhance treatment accessibility, reduce healthcare costs, and improve patient outcomes. Biosimilars for plaque psoriasis are lower-cost, highly similar alternatives to approved biologic drugs used to treat the chronic autoimmune skin condition characterized by red, scaly patches. For instance, in May 2025, Sandoz Group AG, a Switzerland-based company that focuses on generic pharmaceuticals and biosimilars, launched the Pyzchiva autoinjector, the first commercially available ustekinumab biosimilar autoinjector. Pyzchiva is approved for the treatment of adults with plaque psoriasis, psoriatic arthritis, and Crohn's disease, as well as pediatric patients aged six years and older (weighing over 60 kg) with plaque psoriasis. Designed to enhance patient adherence and quality of life, the autoinjector features accurate automatic dosing, reduced injection pain, a compact design, and flexible storage options for more comfortable self-administration.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Psoriasis Biosimilars Market?

In September 2023, Sandoz Group AG, a Switzerland-based pharmaceutical company, partnered with Samsung Bioepis to commercialize the biosimilar SB17 (ustekinumab). This collaboration leverages the strengths of both companies to bring the ustekinumab biosimilar, used to treat conditions such as plaque psoriasis, to markets in Europe and North America. The partnership aims to expand patient access to high-quality, cost-effective immunology treatments while reinforcing Sandoz’s leadership in the global biosimilars market. Samsung Bioepis is a South Korea-based biopharmaceutical company focused on developing and commercializing biosimilar drugs, including those used to treat plaque psoriasis.

Regional Insights

North America was the largest region in the psoriasis biosimilars market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Psoriasis Biosimilars Market?

The psoriasis biosimilars market consists of sales of tumor necrosis factor inhibitors, monoclonal antibodies, subcutaneous and intravenous formulations, subcutaneous injections, and interleukin inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Psoriasis Biosimilars Market Report 2026?

The psoriasis biosimilars market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the psoriasis biosimilars industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Psoriasis Biosimilars Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$9.08 billion
Revenue Forecast In 2035	$13.79 billion
Growth Rate	CAGR of 11.3% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Drug Class, Disease Type, Route Of Administration, Distribution Channel
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	Pfizer Inc., Amgen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis Co. Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Bio-Thera Solutions L
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Psoriasis Biosimilars Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Psoriasis Biosimilars Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Psoriasis Biosimilars Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Psoriasis Biosimilars Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Digitalization, Cloud, Big Data & Cybersecurity

4.1.3 Industry 4.0 & Intelligent Manufacturing

4.1.4 Artificial Intelligence & Autonomous Intelligence

4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems

4.2. Major Trends

4.2.1 Rising Adoption Of Cost-Effective Psoriasis Biosimilars

4.2.2 Increased Focus On Patient Access And Affordability

4.2.3 Growth In Subcutaneous And Intravenous Administration Routes

4.2.4 Expansion Of Hospital And Retail Pharmacy Distribution Channels

4.2.5 Development Of Targeted Therapies For Different Psoriasis Types

5. Psoriasis Biosimilars Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Retail Pharmacies

5.3 Online Pharmacies

5.4 Dermatology Clinics

5.5 Specialty Care Centers

6. Psoriasis Biosimilars Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Psoriasis Biosimilars Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Psoriasis Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Psoriasis Biosimilars Market Size, Comparisons And Growth Rate Analysis

7.3. Global Psoriasis Biosimilars Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Psoriasis Biosimilars Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Psoriasis Biosimilars Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Psoriasis Biosimilars Market Segmentation

9.1. Global Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, Other Biosimilars

9.2. Global Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis

9.3. Global Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Subcutaneous, Intravenous, Oral, Topical

9.4. Global Psoriasis Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

9.5. Global Psoriasis Biosimilars Market, Sub-Segmentation Of TNF-Alpha Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Monoclonal Antibody Biosimilars, Fusion Protein Biosimilars

9.6. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Infliximab, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Remicade Biosimilars, CT-P13 Biosimilars

9.7. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Etanercept, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Enbrel Biosimilars, SB4 Biosimilars

9.8. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Adalimumab, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Humira Biosimilars, ABP 501 Biosimilars

9.9. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Other Biosimilars, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Ustekinumab Biosimilars, Secukinumab Biosimilars

10. Psoriasis Biosimilars Market Regional And Country Analysis

10.1. Global Psoriasis Biosimilars Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Psoriasis Biosimilars Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Psoriasis Biosimilars Market

11.1. Asia-Pacific Psoriasis Biosimilars Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Psoriasis Biosimilars Market

12.1. China Psoriasis Biosimilars Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Psoriasis Biosimilars Market

13.1. India Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Psoriasis Biosimilars Market

14.1. Japan Psoriasis Biosimilars Market Overview

14.2. Japan Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Psoriasis Biosimilars Market

15.1. Australia Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Psoriasis Biosimilars Market

16.1. Indonesia Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Psoriasis Biosimilars Market

17.1. South Korea Psoriasis Biosimilars Market Overview

17.2. South Korea Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Psoriasis Biosimilars Market

18.1. Taiwan Psoriasis Biosimilars Market Overview

18.2. Taiwan Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Psoriasis Biosimilars Market

19.1. South East Asia Psoriasis Biosimilars Market Overview

19.2. South East Asia Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Psoriasis Biosimilars Market

20.1. Western Europe Psoriasis Biosimilars Market Overview

20.2. Western Europe Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Psoriasis Biosimilars Market

21.1. UK Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Psoriasis Biosimilars Market

22.1. Germany Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Psoriasis Biosimilars Market

23.1. France Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Psoriasis Biosimilars Market

24.1. Italy Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Psoriasis Biosimilars Market

25.1. Spain Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Psoriasis Biosimilars Market

26.1. Eastern Europe Psoriasis Biosimilars Market Overview

26.2. Eastern Europe Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Psoriasis Biosimilars Market

27.1. Russia Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Psoriasis Biosimilars Market

28.1. North America Psoriasis Biosimilars Market Overview

28.2. North America Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Psoriasis Biosimilars Market

29.1. USA Psoriasis Biosimilars Market Overview

29.2. USA Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Psoriasis Biosimilars Market

30.1. Canada Psoriasis Biosimilars Market Overview

30.2. Canada Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Psoriasis Biosimilars Market

31.1. South America Psoriasis Biosimilars Market Overview

31.2. South America Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Psoriasis Biosimilars Market

32.1. Brazil Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Psoriasis Biosimilars Market

33.1. Middle East Psoriasis Biosimilars Market Overview

33.2. Middle East Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Psoriasis Biosimilars Market

34.1. Africa Psoriasis Biosimilars Market Overview

34.2. Africa Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Psoriasis Biosimilars Market Regulatory and Investment Landscape

36. Psoriasis Biosimilars Market Competitive Landscape And Company Profiles

36.1. Psoriasis Biosimilars Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Psoriasis Biosimilars Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Psoriasis Biosimilars Market Company Profiles

36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Sandoz Group AG Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Intas Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis

37. Psoriasis Biosimilars Market Other Major And Innovative Companies

STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis Co. Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Alvotech hf.

38. Global Psoriasis Biosimilars Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Psoriasis Biosimilars Market

40. Psoriasis Biosimilars Market High Potential Countries, Segments and Strategies

40.1 Psoriasis Biosimilars Market In 2030 - Countries Offering Most New Opportunities

40.2 Psoriasis Biosimilars Market In 2030 - Segments Offering Most New Opportunities

40.3 Psoriasis Biosimilars Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Psoriasis Biosimilars Market, Overview Of Key Products - Product Examples

Table 2: Global Psoriasis Biosimilars Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Psoriasis Biosimilars Market, Supply Chain Analysis

Table 4: Global Psoriasis Biosimilars Market, Major Raw Material Providers

Table 5: Global Psoriasis Biosimilars Market, Major Resource Providers

Table 6: Global Psoriasis Biosimilars Market, Major Manufacturers (Suppliers)

Table 7: Global Psoriasis Biosimilars Market, Major Distributors And Channel Partners

Table 8: Global Psoriasis Biosimilars Market, Key Technologies & Future Trends

Table 9: Global Psoriasis Biosimilars Market, Major Trends

Table 10: Global Psoriasis Biosimilars Market, Major End Users

Table 11: Global Psoriasis Biosimilars Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Psoriasis Biosimilars Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Psoriasis Biosimilars Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Psoriasis Biosimilars Market - TAM, US$ Billion, 2025

Table 15: Global Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Psoriasis Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Psoriasis Biosimilars Market, Sub-Segmentation Of TNF-Alpha Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global Psoriasis Biosimilars Market, Sub-Segmentation Of Infliximab, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global Psoriasis Biosimilars Market, Sub-Segmentation Of Etanercept, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Global Psoriasis Biosimilars Market, Sub-Segmentation Of Adalimumab, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Global Psoriasis Biosimilars Market, Sub-Segmentation Of Other Biosimilars, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Global Psoriasis Biosimilars Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: Global Psoriasis Biosimilars Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: Asia-Pacific, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: Asia-Pacific, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: Asia-Pacific, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: China, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: China, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: China, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: India, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: India, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: India, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: Japan, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Japan, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Japan, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Australia, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Australia, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Australia, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: Indonesia, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: Indonesia, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: Indonesia, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: South Korea, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: South Korea, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: South Korea, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: Taiwan, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: Taiwan, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: Taiwan, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: South East Asia, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: South East Asia, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: South East Asia, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: Western Europe, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: Western Europe, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: Western Europe, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: UK, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: UK, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: UK, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: Germany, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: Germany, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: Germany, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: France, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: France, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: France, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: Italy, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Italy, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Italy, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Spain, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Spain, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Spain, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Eastern Europe, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Eastern Europe, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: Eastern Europe, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: Russia, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: Russia, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: Russia, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: North America, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: North America, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: North America, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: USA, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: USA, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: USA, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: Canada, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: Canada, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: Canada, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: South America, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: South America, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: South America, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: Brazil, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Brazil, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Brazil, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Middle East, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Middle East, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Middle East, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 95: Africa, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 96: Africa, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 97: Africa, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 98: Global Psoriasis Biosimilars Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 99: Global Psoriasis Biosimilars Market - Company Scoring Matrix

Table 100: Pfizer Inc. Financial Performance

Table 101: Amgen Inc. Financial Performance

Table 102: Sandoz Group AG Financial Performance

Table 103: Fresenius Kabi AG Financial Performance

Table 104: Intas Pharmaceuticals Ltd. Financial Performance

Table 105: Global Psoriasis Biosimilars Market, Competitive Benchmarking (In USD Billions)

Table 106: Global Psoriasis Biosimilars Market, Competitive Dashboard

Table 107: Global Psoriasis Biosimilars Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 108: Global, Psoriasis Biosimilars Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030

Table 109: Global, Psoriasis Biosimilars Market Size Gain ($ Billion), Segmentation By Disease Type, 2025 – 2030

Table 110: Global, Psoriasis Biosimilars Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030

List Of Figures

Figure 1: Global Psoriasis Biosimilars Market, Overview Of Key Products - Product Examples

Figure 2: Global Psoriasis Biosimilars Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Psoriasis Biosimilars Market, Supply Chain Analysis

Figure 4: Global Psoriasis Biosimilars Market, Major Raw Material Providers

Figure 5: Global Psoriasis Biosimilars Market, Major Resource Providers

Figure 6: Global Psoriasis Biosimilars Market, Major Manufacturers (Suppliers)

Figure 7: Global Psoriasis Biosimilars Market, Major Distributors And Channel Partners

Figure 8: Global Psoriasis Biosimilars Market, Key Technologies & Future Trends

Figure 9: Global Psoriasis Biosimilars Market, Major Trends

Figure 10: Global Psoriasis Biosimilars Market, Major End Users

Figure 11: Global Psoriasis Biosimilars Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Psoriasis Biosimilars Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Psoriasis Biosimilars Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Psoriasis Biosimilars Market - TAM, US$ Billion, 2025

Figure 15: Global Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Psoriasis Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Psoriasis Biosimilars Market, Sub-Segmentation Of TNF-Alpha Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global Psoriasis Biosimilars Market, Sub-Segmentation Of Infliximab, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global Psoriasis Biosimilars Market, Sub-Segmentation Of Etanercept, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Global Psoriasis Biosimilars Market, Sub-Segmentation Of Adalimumab, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Global Psoriasis Biosimilars Market, Sub-Segmentation Of Other Biosimilars, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Global Psoriasis Biosimilars Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: Global Psoriasis Biosimilars Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: Asia-Pacific, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: Asia-Pacific, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: Asia-Pacific, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: China, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: China, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: China, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: India, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: India, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: India, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: Japan, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Japan, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Japan, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Australia, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Australia, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Australia, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: Indonesia, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: Indonesia, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: Indonesia, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: South Korea, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: South Korea, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: South Korea, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: Taiwan, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: Taiwan, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: Taiwan, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: South East Asia, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: South East Asia, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: South East Asia, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: Western Europe, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: Western Europe, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: Western Europe, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: UK, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: UK, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: UK, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: Germany, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: Germany, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: Germany, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: France, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: France, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: France, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: Italy, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Italy, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Italy, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Spain, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Spain, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Spain, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Eastern Europe, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Eastern Europe, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: Eastern Europe, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: Russia, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: Russia, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: Russia, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: North America, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: North America, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: North America, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: USA, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: USA, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: USA, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: Canada, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: Canada, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: Canada, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: South America, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: South America, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: South America, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: Brazil, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Brazil, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Brazil, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Middle East, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Middle East, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Middle East, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 95: Africa, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 96: Africa, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 97: Africa, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 98: Global Psoriasis Biosimilars Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 99: Global Psoriasis Biosimilars Market - Company Scoring Matrix

Figure 100: Pfizer Inc. Financial Performance

Figure 101: Amgen Inc. Financial Performance

Figure 102: Sandoz Group AG Financial Performance

Figure 103: Fresenius Kabi AG Financial Performance

Figure 104: Intas Pharmaceuticals Ltd. Financial Performance

Figure 105: Global Psoriasis Biosimilars Market, Competitive Benchmarking (In USD Billions)

Figure 106: Global Psoriasis Biosimilars Market, Competitive Dashboard

Figure 107: Global Psoriasis Biosimilars Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 108: Global, Psoriasis Biosimilars Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030

Figure 109: Global, Psoriasis Biosimilars Market Size Gain ($ Billion), Segmentation By Disease Type, 2025 – 2030

Figure 110: Global, Psoriasis Biosimilars Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

Rail Road Construction Market Report 2026 - Global Outlook – By Train Type (Metro, Light Rail, Bullet Train Or High-Speed Rail (HSR) ), By Construction Type (New Construction, Renovation), By Application (Urban, Rural ) ...

Freight Railcar Parts Market Report 2026 - Global Outlook – By Component (Gears, Wheels, Axles And Bearings, Side Frames, Draft Systems, Couplers And Yokes, Airbrakes, Other Components), By Type (Autocar, Box Car, Center...

Cross Laminated Timber Market Report 2026 - Global Outlook – By Product Type (3-Ply CLT Panels, 5-Ply CLT Panels, 7-Ply and Above CLT Panels), By Application (Walls, Floors, Roofs), By End-Use Sector (Residential, Commer...

Passenger Rail Transport Market Report 2026 - Global Outlook – By Type (Medium-Distance Passenger Transport; Long-Distance Passenger Transport; Short-Distance Passenger Transport), By Service Type (Core Passenger Transpo...

Rail Road Construction Market Report 2026 - Global Outlook – By Train Type (Metro, Light Rail, Bullet Train Or High-Speed Rail (HSR) ), By Construction Type (New Construction, Renovation), By Application (Urban, Rural ) ...

Rail Asset Management Market Report 2026 - Global Outlook – By Solution (Asset Performance Management, Analytics, Asset Planning And Scheduling, Security, Workforce Management, Other Solutions), By Services (Professional...

Finger Print Vehicle Access Market Report 2026 - Global Outlook – By Type (Fingerprint Opens The Door, Fingerprint Ignition), By Vehicle (Passenger Car, Battery Electric Vehicle), By Application (Door, On Board) – Market...

Frequently Asked Questions

How big is the Psoriasis Biosimilars Market?

The Psoriasis Biosimilars market was valued at $8.16 billion in 2025, increased to $9.08 billion in 2026, and is projected to reach $13.79 billion by 2030.

What is the Psoriasis Biosimilars market growth?

The global Psoriasis Biosimilars market is expected to grow at a CAGR of 11.0% from 2026 to 2035 to reach $13.79 billion by 2035.

Who are the key players in Psoriasis Biosimilars market?

Some Key Players in the Psoriasis Biosimilars market Include, Pfizer Inc., Amgen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis Co. Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Alvotech hf. .

What is the anticipated growth trend for the Psoriasis Biosimilars market?

Major trend in this market includes: Launch Of First Ustekinumab Biosimilar Autoinjector Enhances Plaque Psoriasis Treatment Options. For further insights on this market. request a sample here

Which region has the most growth potential in the Psoriasis Biosimilars market?

North America was the largest region in the psoriasis biosimilars market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psoriasis biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.